20/20 Biolabs Inc.
AIDXNASDAQHealthcareMedical - Care Facilities
Previous close
$0.5543
+$0.0402 · +7.82%
AIDX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
82
Deep Value
Momentum
17
Strong Down
Sentiment
58
Mixed
Risk resilience
21
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company website20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jonathan Cohen
- Listed since
- Feb 19, 2026
- Employees
- 14
Market position
Day range
Current $0.5543
52-week range
Current $0.5543
- Open
- $0.5241
- Previous close
- $0.5141
- Volume
- 230.86K
- 0.39× average
- Average volume
- 586.96K
- Average daily volume
- Market cap
- 6.79M USD
- Beta
- 1.54
- Market reference 1
- 50-day average
- $0.549
- +0.97% above average
- 200-day average
- $1.7131
- -67.64% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 407.26M USD
- P/E (TTM)
- -0.66×
- P/B (TTM)
- 1.89×
- P/S (TTM)
- 3.33×
- EV / EBITDA
- -116.21×
- Earnings yield
- -2.51%
- Free cash flow yield
- -1286.50%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 31.52%
- Operating margin
- -215.69%
- Net margin
- -285.00%
- Return on equity
- 19.45%
- Return on assets
- -0.09%
- Return on invested capital
- -0.18%
Financial health
- Debt / equity
- 0.18×
- Current ratio
- 0.6×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.05M USD | 1.75M USD | 1.42M USD | 11.06M USD | 9.62M USD |
| Cost of goods sold | 1.44M USD | 1.39M USD | 1.32M USD | 5.94M USD | 4.93M USD |
| Gross profit | 604.54K USD | 360.31K USD | 109.14K USD | 5.12M USD | 4.69M USD |
| Research and development | 592.57K USD | 1.26M USD | 1.41M USD | 120.04K USD | 193.37K USD |
| Selling, general, and administrative | 3.34M USD | 4.76M USD | 5.06M USD | 3.32M USD | 2.56M USD |
| Operating expenses | 3.94M USD | 6.02M USD | 6.47M USD | 3.44M USD | 2.75M USD |
| Interest income | 21.4K USD | 79.47K USD | 209.15K USD | 68.42K USD | 2.99K USD |
| Interest expense | 156.21K USD | 12.65K USD | 27.92K USD | 15.69K USD | 12.93K USD |
| Depreciation and amortization | 77.98K USD | 135.76K USD | 167.29K USD | 288.69K USD | 123.66K USD |
| Operating income | −3.33M USD | −5.66M USD | −6.36M USD | 1.68M USD | 1.94M USD |
| Net income | −3.74M USD | −5.55M USD | −6.39M USD | 2.19M USD | 2.07M USD |
Company facts updated Aug 24, 2026.
AIDX news
AIDX peers
ETFs holding AIDX
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research AIDXresearch.disclaimer